The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
P/E ratio for AbbVie (ABBV)
P/E ratio as of March 2023 (TTM): 23.3
According to AbbVie's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.2989. At the end of 2021 the company had a P/E ratio of 20.7.
P/E ratio history for AbbVie from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 20.7 | -42.97% |
| 2020 | 36.3 | 118.84% |
| 2019 | 16.6 | -34.15% |
| 2018 | 25.2 | -13.12% |
| 2017 | 29.0 | 70.73% |
| 2016 | 17.0 | -9.1% |
| 2015 | 18.7 | -68.14% |
| 2014 | 58.7 | 189.17% |
| 2013 | 20.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 7.54 | -67.64% | 🇺🇸 USA |
 Eli Lilly LLY | 49.7 | 113.20% | 🇺🇸 USA |
 Amgen AMGN | 18.7 | -19.69% | 🇺🇸 USA |
 Biogen BIIB | 12.6 | -45.87% | 🇺🇸 USA |
 Gilead Sciences GILD | 29.7 | 27.26% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 21.5 | -7.87% | 🇺🇸 USA |
 AstraZeneca AZN | 102 | 338.18% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 4.10 | -82.38% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 157 | 573.99% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.